Eris Lifesciences Limited reappoints MD and Whole-Time Director
Posted On: 2021-04-01 03:01:53 (Time Zone: Arizona, USA)
Based on the recommendation of the Nomination and Remuneration Committee and their own consideration, the Board of Directors of Eris Lifesciences Limited at their meeting held on 31st March 2021 has approved the re-appointment of Mr. Amit Bakshi (DIN: 01250925) as a Managing Director of the Company for a further period of five (5) years with effect from April 1st 2021, subject to the approval of the shareholders, in the usual course.
The board also approved the re-appointment of Mr. Inderjeet Singh Negi (DIN: 01255388) as a Whole-Time Director of the Company for a further period of five (5) years with effect from April 1st 2021, subject to the approval of the shareholders, in the usual course.
Ahmedabad-based drug maker Eris Lifesciences Ltd. has posted a 42 per cent rise in its consolidated net profit for the third quarter of financial year 2020-21 at Rs 90.1 crore. Last year the company registered a consolidated Q3 net profit of Rs 63.4 crore. The company s consolidated total income grew by 14 per cent to Rs 313.4 crore in the said quarter, as compared to Rs 274.8 crore in Q3 the previous fiscal. Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients (VMN). Excluding Covid molecules, the company saw a year-on-year (YoY) growth of 15.6 per cent as against a five per cent growth by the Indian Pharmaceutical Market (IPM) in Q3 of FY 21.
Eris Lifesciences Ltd posts consolidated PAT of Rs. 90.15 crore in Q3FY21
Posted On:
Eris Lifesciences Ltd has reported financial results for the period ended December 31, 2020.
Financial Results (Q3 FY20-21) - QoQ Comparison
The company has reported total income of Rs.313.49 crores during the period ended December 31, 2020 as compared to Rs.332.07 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.90.15 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.107.72 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.6.63 for the period ended December 31, 2020 as compared to Rs.7.93 for the period ended September 30, 2020.
Eris Lifesciences Limited appoints Mr. Rajeev Dalal as an Additional Independent Director
Posted On: 2020-12-20 05:32:12 (Time Zone: Arizona, USA)
Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of Eris Lifesciences Limited have passed a circular resolution on December 19, 2020, approving appointment of Mr. Rajeev Dalal (DIN : 00222650) as an Additional Director (Non‐Executive Independent Director) on the Board of Directors of the Company with effect from December 19, 2020 for a term of 5 (five) years upto December 18, 2025, subject to approval of the Shareholders of the Company.
Profile Summary of Mr. Rajeev Dalal: Mr. Rajeev Dalal is a Member of the Institute of Company Secretaries of India. Further he also holds degree of Bachelor of Law and Bachelor of Commerce. He has also been a member of the Committee appointed by the Securities Exchange Board of India (SEBI) for improving disclosure standards in public documents o